TEOXANE Laboratories in the news

Revance introduced the Teoxane RHA® dermal filler line with mepivacaine anesthetic, improving patient comfort and reducing bruising risks compared to lidocaine.

The aesthetic fillers market is expected to nearly double by 2032, driven by strong growth and competitive activity among key players including Teoxane Laboratories.

Teoxane SA offered to buy Revance Therapeutics at a 16% premium, leveraging their existing partnership and financial strength to propose a swift acquisition.

TEOXANE Laboratories has submitted a competing bid to acquire Revance Therapeutics, complicating an earlier acquisition plan by Crown Laboratories due to a contract dispute with a Swiss partner.

Revance Therapeutics expanded and revised its distribution agreements with Teoxane SA, including new rights in Australia and New Zealand, while progressing a merger with Crown Laboratories amid strong revenue growth but ongoing profitability challenges.

Hyaluronic acid treatments are increasingly popular, with Teoxane Laboratories pioneering natural, dynamic fillers certified under MDR for safer, more effective anti-aging results.

This article spotlights five aesthetic brands founded by women, showcasing their innovative contributions to the cosmetic industry, including Teoxane Laboratories' RHA fillers for dynamic facial wrinkles.

Teoxane develops patented RHA-based dermal fillers and skincare products that mimic natural hyaluronic acid, focusing on safety, efficacy, and natural beauty.

Hyaluronic acid soft-tissue fillers use BDDE crosslinking to enhance durability and performance, with new methods emerging but needing further validation.

Teoxane's 'Teosyal Rha4' hyaluronic acid filler won a 2017 beauty award for its innovative support of skin vitality and elasticity during facial movement.

Teoxane's Teosyal RHA 4 hyaluronic acid filler won the "Anti-Aging & Beauty Trophy 2017" for its innovative approach to facial volume and elasticity.